SCHEMBL21775792

SCHEMBL21775792

CCOc1ccc(-c2cc3nc(C)c(SC)c(N4CCCC(C(=O)O)C4)n3n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.51
ALDH1A1 P00352 8/20 0.51
KDM4E B2RXH2 7/20 0.51
HSD17B10 Q99714 3/20 0.51
HPGD P15428 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
TP53 P04637 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
HTT P42858 1/20 0.51
POLB P06746 3/20 0.47
LMNA P02545 6/20 0.44
TSHR P16473 2/20 0.44
ABCB1 P08183 1/20 0.44
NPSR1 Q6W5P4 3/20 0.44
USP2 O75604 1/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21775642 0.89 KDM4E (0.46) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21774123 0.88 KDM4E (0.56) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21775583 0.88 KDM4E (0.56) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21775793 0.86 KDM4E (0.44) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21775694 0.86 KDM4E (0.46) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21775789 0.86 KDM4E (0.47) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21775695 0.86 KDM4E (0.47) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21775878 0.84 KDM4E (0.47) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21775683 0.82 KDM4E (0.62) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21774117 0.82 KDM4E (0.44) MAPTALDH1A1KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10960007-B2 Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives RICHTER GEDEON NYRT. (HU) 2021-03-30 US disclosed
US-20200061068-A1 Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives RICHTER GEDEON NYRT. (HU) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200061068-A1 Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives GABRA5, P2RX5, P2RY1 MAPT 2067/4885ALDH1A1 585/4885KDM4E 2972/4885
US-10960007-B2 Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives GABRA5, P2RX5, P2RY1 MAPT 2067/4885ALDH1A1 585/4885KDM4E 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.